UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2019

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-16407   13-4151777

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value   ZBH   New York Stock Exchange
1.414% Notes due 2022   ZBH 22A   New York Stock Exchange
2.425% Notes due 2026   ZBH 26   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b), (c), (e) – On June 19, 2019, Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) announced that Daniel P. Florin will be retiring as Executive Vice President and Chief Financial Officer of the Company and Suketu Upadhyay has been appointed to succeed Mr. Florin effective July 1, 2019. Mr. Florin will continue with Zimmer Biomet in an advisory capacity for a transition period. A copy of the related press release is furnished with this report as Exhibit 99.1.

Mr. Upadhyay, age 50, joins Zimmer Biomet from Bristol-Myers Squibb Company, where he has served as Senior Vice President, Global Financial Operations since November 2016. Before joining Bristol-Myers Squibb, he served as Executive Vice President, Chief Financial Officer of Endo International plc from September 2013 to November 2016. Prior to that, Mr. Upadhyay held leadership positions at Becton, Dickinson & Company as Controller and Chief Accounting Officer and as Interim Chief Financial Officer. He also held leadership roles with Johnson & Johnson and AstraZeneca. Mr. Upadhyay began his career with KPMG and has held the designations of Certified Public Accountant and Certified Management Accountant.

Mr. Florin currently serves as the Company’s principal accounting officer and will also retire from that role effective July 1, 2019. As a result, beginning effective July 1, 2019, Mr. Upadhyay will serve as Zimmer Biomet’s principal financial officer and, for a period of time until the Company concludes its previously announced search for a new principal accounting officer, Mr. Upadhyay will also serve as the Company’s principal accounting officer.

There are no arrangements or understandings between Mr. Upadhyay and any other persons pursuant to which he was selected as an officer of the Company. He has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and he does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.

Mr. Upadhyay’s employment with Zimmer Biomet will be on an at-will basis. In connection with his appointment, Mr. Upadhyay accepted a written offer letter from the Company that provides for the following compensation:

 

   

an initial annualized base salary of $675,000;

 

   

eligibility for an annual incentive payout under the Company’s Executive Performance Incentive Plan for 2019 based on a target bonus opportunity of 90% of base salary (to be prorated for a partial year of service in 2019), subject to the attainment of pre-established performance goals;

 

   

eligibility for a long-term incentive plan award in 2020 under the Company’s 2009 Stock Incentive Plan (the “2009 Plan”) with a grant date fair value of approximately $2,400,000; Zimmer Biomet’s long-term incentive plan awards currently provide for grants of stock options and performance-based restricted stock units;

 

   

a make-whole, sign-on bonus of $1,358,000 intended to replace the following estimated amounts that Mr. Upadhyay will forfeit or be required to repay upon leaving his current employer to join Zimmer Biomet: (i) $260,000 forfeiture of prorated annual bonus for the current year, (ii) $917,000 repayment obligation related to a sign-on bonus he received from his current employer, and (iii) $181,000 forfeiture of employer retirement plan contributions; Mr. Upadhyay must repay to Zimmer Biomet the entire gross amount of this make-whole, sign-on bonus if he voluntarily leaves employment or if his employment is terminated for cause within two years of the date the bonus is paid to him;

 

   

a make-whole, sign-on equity award under the 2009 Plan with a grant date fair value of approximately $3,376,000 intended to replace the value of equity awards that Mr. Upadhyay will forfeit upon leaving his current employer to join Zimmer Biomet; this award will be in the form of 50% stock options and 50% restricted stock units and will vest 25% per year over four years, subject to continued employment on the applicable vesting date, beginning on the first anniversary of the grant date, which will be Mr. Upadhyay’s first day of employment with Zimmer Biomet;

 

   

an inducement, sign-on equity award under the 2009 Plan with a grant date fair value of approximately $500,000 in the form of performance-based restricted stock units, with performance to be measured based on the Company’s total shareholder return relative to the S&P 500 Healthcare Index constituents over a three-year performance period beginning on the grant date of the award, which will be Mr. Upadhyay’s first day of employment with Zimmer Biomet;


   

a one-time commuting allowance of $252,000; Mr. Upadhyay will be responsible for all expenses associated with commuting from his home to the Company’s Connecticut office and will be required to repay to Zimmer Biomet the entire gross amount of this allowance if he voluntarily leaves employment or if his employment is terminated for cause within two years of the date the allowance is paid to him;

 

   

severance benefits upon a change in control of the Company and an involuntary termination of Mr. Upadhyay’s employment without cause or a termination by him with good reason pursuant to a change in control severance agreement to be entered into between Mr. Upadhyay and the Company in the form filed as Exhibit 10.11 to the Company’s Annual Report on Form 10-K filed February 26, 2019, which is incorporated herein by reference as Exhibit 10.2; a summary of the agreement is included in the Company’s Proxy Statement filed March 27, 2019 under “Executive Compensation – Potential Payments upon Termination of Employment – Change in Control Arrangements”;

 

   

severance benefits in the event of involuntary termination without cause as a participant under the Restated Zimmer Biomet Holdings, Inc. Executive Severance Plan, which was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed August 6, 2018 and is incorporated herein by reference as Exhibit 10.3; a summary of the plan is included in the Company’s Proxy Statement filed March 27, 2019 under “Executive Compensation – Potential Payments upon Termination of Employment –Executive Severance Plan”; and

 

   

relocation assistance and certain other benefits described in the offer letter.

The foregoing summary of the offer letter is qualified in its entirety by reference to the full text of the offer letter, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference. Mr. Upadhyay also executed a Confidentiality, Non-Competition and Non-Solicitation Agreement as a condition of and in consideration for employment with Zimmer Biomet, the form of which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed February 26, 2019 and is incorporated herein by reference as Exhibit 10.4; a summary of the agreement is included in the Company’s Proxy Statement filed March 27, 2019 under “Executive Compensation – Potential Payments upon Termination of Employment – Non-Compete Arrangements”.

 

Item   7.01 .

Regulation FD Disclosure.

The Company issued a press release on June 19, 2019 announcing the leadership transition described in Item 5.02 above, which is furnished as Exhibit 99.1 to this report.

The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such disclosure in this Form 8-K in such a filing.

 

Item   9.01 .

Financial Statements and Exhibits .

(d) Exhibits

 

Exhibit

  

Description

10.1    Offer letter between Zimmer Biomet Holdings, Inc. and Suketu Upadhyay dated June 13, 2019
10.2    Form of Change in Control Severance Agreement with Suketu Upadhyay (incorporated by reference to Exhibit 10.11 to the Company’s Annual Report on Form 10-K filed February 26, 2019)
10.3    Restated Zimmer Biomet Holdings, Inc. Executive Severance Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed August 6, 2018)
10.4    Form of Confidentiality, Non-Competition and Non-Solicitation Agreement with Suketu Upadhyay (incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed February 26, 2019)
99.1    Press Release issued by Zimmer Biomet Holdings, Inc. dated June 19, 2019


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2019

 

ZIMMER BIOMET HOLDINGS, INC.
By:  

/s/ Chad F. Phipps

Name:   Chad F. Phipps
Title:   Senior Vice President, General Counsel and Secretary

Exhibit 10.1

 

LOGO

Confidential

June 13, 2019

Suketu Upadhyay

Dear Suketu:

It is a pleasure to offer you the position of Executive Vice President (EVP) and Chief Financial Officer (CFO) of Zimmer Biomet Holdings, Inc. (Zimmer Biomet or the Company) reporting to Bryan C. Hanson, President and Chief Executive Officer. In this role, you will be paid an initial biweekly salary of $25,961.54, which is $675,000 annualized. Your start date will be mutually determined.

The Compensation and Management Development Committee of the Board of Directors of Zimmer Biomet (Compensation Committee) has approved your compensation package as Executive Vice President and CFO. We expect that this role will be designated as a Section 16 Officer by the Board of Directors, as described more fully below. The Board will take separate action to officially make that designation.

Annual Merit Adjustment

Zimmer Biomet’s annual merit review process involves base pay adjustments consistent with job performance. Merit adjustments are based on performance during the calendar year. You will be eligible for a merit increase beginning in 2020.

Executive Performance Incentive Plan (EPIP)

You will be eligible to participate in the 2019 EPIP upon your hire date. Your target bonus incentive will be 90% of your eligible earnings (which will consist primarily of base salary payments) for the year.

Your bonus payout under the EPIP will be based 90% on financial Corporate metric group results and 10% on evaluated accomplishment of your individual goals and objectives. The metrics include Consolidated Operating Earnings (30%), Consolidated Revenue (35%), Consolidated Free Cash Flow (15%) and Adjusted Earnings per Share (20%). Your 2019 bonus will be prorated for a partial year of service based upon your start date by applying the earned bonus percentage to your eligible Zimmer Biomet earnings for the year.

You must remain employed by Zimmer Biomet at the time of bonus payout to be eligible to receive any bonus for the prior calendar year. Payout will occur around March of the year following the year for which the bonus is paid.

2020 Long-Term Incentive (LTI) Plan Award

For 2020, your estimated LTI grant date fair value in this role will be approximately $2,400,000.

Zimmer Biomet LTI Plan grants currently have two components:

 

   

Stock options and

 

   

Performance-based Restricted Stock Units (PRSUs).

 

LOGO    Page 1 – June 13, 2019


LOGO

 

This LTI structure offers participants a diversified award of 50% stock options and 50% PRSUs that can provide more consistent value than an award of stock options alone. Further, we believe this structure helps the Company remain competitive within the global labor market and creates a compelling and valuable long-term incentive for participants. For 2019, there are two Company performance metrics for the PRSUs, with payouts determined based 50% on Zimmer Biomet’s relative total shareholder return (TSR) against the S&P 500 Health Care Index constituents and 50% on Zimmer Biomet’s constant currency revenue growth. The Compensation and Management Development Committee will review and determine the financial metrics that will apply for the PRSU plan for the 2020 grant.

LTI grant values are based upon our compensation philosophy, which is reviewed annually by the Compensation Committee and adjusted as warranted. We will provide additional details and information on this PRSU design in or around February 2020. After reviewing performance metrics, equity award types and value mix to finalize terms of the 2020 annual grant, we will communicate Compensation Committee determinations. Thereafter, applicable performance metrics, equity award types and value mix will remain subject to annual review and approval by the Compensation Committee.

We anticipate the grant date of the 2020 award will be in or around February 2020, subject to the Compensation Committee’s approval. Please keep in mind that your job responsibilities, performance against your goals and objectives, the overall financial results of the Company and peer group / market compensation practices also impact LTI grant values each year.

Former Employer Bonus Forfeiture

Since you will forfeit eligibility to receive a bonus payment for this fiscal year from your current employer due to your separation to accept this role with Zimmer Biomet, we will pay you a one-time cash bonus forfeiture amount to approximate your foregone bonus at your former company. We estimate your bonus forfeiture at $260,000. Please provide the appropriate documentation to support this amount as soon as you are able. Upon acceptance of the documentation and your commencement of employment, we will process payment within 90 days of your start date. This bonus forfeiture payment will not be included as income for purposes of calculating any other bonus or determining compensation for any benefit plan purposes, and will be subject to applicable tax withholdings. As a condition of payment, you must agree by your signature below that you will repay to Zimmer Biomet the entire gross amount paid to you if you voluntarily leave employment or if your employment with Zimmer Biomet is terminated for cause prior to the two-year anniversary of the date Zimmer Biomet makes this payment to you.

Sign-On/Inducement and Make-Whole/Replacement Equity Grants

In connection with your commencement of employment, Zimmer Biomet will provide you a one-time long-term incentive grant with a grant date fair value of approximately $3,876,000. This will consist of (1) a sign-on/inducement equity grant with a grant date fair value of approximately $500,000; and (2) a make-whole/replacement equity grant with a grant date fair value of approximately $3,376,000.

 

LOGO    Page 2 – June 13, 2019


LOGO

 

   

The sign-on/inducement equity grant ($500,000 grant date fair value) will consist of 100% PRSUs. The grant date will be your first business day of employment with the Company. Performance will be measured by relative TSR over a three-year performance period (beginning on the grant date of the award) versus the TSR of S&P 500 Healthcare Index constituents (Index). We will use a 20-consecutive-trading-day average for the beginning and ending periods for both the ZBH stock price and the Index. The performance scale is as follows: below 25 th percentile performance = 0% payout, 25 th percentile performance = 50% payout, 50 th percentile performance = target payout, 75 th percentile performance = 150% payout and 90 th percentile performance or higher = 200% payout. For performance between these percentiles, the payout is interpolated.

 

   

The make-whole/replacement equity grant of $3,376,000 will consist of 50% stock options and 50% time-vested restricted stock units (RSUs) (based on the grant date fair value of such awards). The grant date will be your first business day of employment with the Company. The stock options will vest at the rate of 25% per year over four years beginning on the first anniversary of the grant date, assuming your continued employment with Zimmer Biomet, and will expire on the tenth anniversary of the grant date. As with the stock option award, the grant date for the RSUs will be your first business day of employment with the Company. These RSUs will vest at the rate of 25% per year over four years beginning on the first anniversary of the date of the grant, again assuming your continued employment with Zimmer Biomet.

All equity awards (including the sign-on/inducement and make-whole/replacement equity grants and the 2020 Long-Term Incentive Plan Award) are subject to the terms and conditions of the 2009 Stock Incentive Plan, as amended from time to time; award agreements; your execution of a non-disclosure, intellectual property and restrictive covenant agreement in the form provided by the Company; and your continued Company employment on applicable grant and vesting dates.

Former Employer Repayment Obligations

It is our understanding that upon your resignation you will owe your former employer approximately $917,000 as repayment of a sign-on-bonus you received. Please provide the appropriate documentation to support the amount owed to your former employer. We will process payment within 90 days of your start date subject to our receipt of this documentation in satisfactory form. After reimbursement of this amount, you will be responsible for making this payment to your former employer. This payment will not be included as income for purposes of calculating any other bonus or determining compensation for any benefit plan purposes, and will be subject to applicable tax withholdings. As a condition of payment, you must agree by your signature below that you will repay to Zimmer Biomet the entire gross amount paid to you if you voluntarily leave employment or if your Zimmer Biomet employment is terminated for cause prior to the two-year anniversary of the date Zimmer Biomet makes this payment to you.

 

LOGO    Page 3 – June 13, 2019


LOGO

 

Miscellaneous Reimbursement of Former Employer

Since you will forfeit prior employer contributions to retirement accounts in 401(k) and Supplemental Executive Savings plans in the amount of $181,000, we will process payment to you in this amount within 90 days of your start date. This payment will not be included as income for purposes of calculating any other bonus or determining compensation for any benefit plan purposes, and will be subject to applicable tax withholdings. As a condition of payment, you must agree by your signature below that you will repay to Zimmer Biomet the entire gross amount paid to you if you voluntarily leave employment or if your Zimmer Biomet employment is terminated for cause prior to the two-year anniversary of the date Zimmer Biomet makes this payment to you.

U.S. Deferred Compensation Plan

You will be eligible to participate in the Zimmer Biomet Deferred Compensation Plan in 2020.

The Deferred Compensation Plan offers:

 

   

Savings opportunities through voluntary deferrals and Company matching contributions;

 

   

Pre-tax earnings to help your account grow faster; and

 

   

In-service distribution options to help you plan for future events.

Key features include:

 

   

The ability to defer up to 50% of your base salary and up to 95% of your annual bonus.

 

   

Matching contributions of 100% of your contribution up to a maximum of 6% of base salary and bonus, minus 401(k) matching contributions.

This plan is a nonqualified deferred compensation plan funded solely from the Company’s general assets.

Change In Control (CIC) Severance Agreement

In your role, you will be offered a CIC Severance Agreement, subject to your execution of the enclosed non-disclosure, intellectual property and restrictive covenant agreement. The CIC Severance Agreement would provide you an enhanced severance benefit opportunity for a period of time following a change in control of Zimmer Biomet should your employment be terminated by the Company without cause or by you for good reason, both as defined in the agreement. Once you return the enclosed non-disclosure, intellectual property and restrictive covenant agreement, we will prepare the CIC Severance Agreement along with a cover memo outlining the benefits under the agreement. Your continued eligibility for potential CIC severance benefits in the event of a change in control would be in accordance with the terms of the agreement.

Executive Severance Plan

In your role, you will be eligible to participate in our Executive Severance Plan. As an eligible Leadership Team member, in the event of your involuntary separation from employment without cause as defined under the plan, your severance benefit offer would include the sum of your final base salary and final target bonus, plus 12 months of COBRA premium subsidy (medical and dental) based on your coverage in effect immediately prior to your separation. Payment would be made in lump-sum form, less applicable tax withholdings, subject to your entering into a general release in the form provided by the Company. There would be no duplication of benefits provided under the CIC Severance Agreement or otherwise. Your continued eligibility for participation in this plan will be in accordance with the terms of the plan as defined and administered by the Company.

 

LOGO    Page 4 – June 13, 2019


LOGO

 

One-Time Commuting Allowance

Since you will commute from your home to our Connecticut office, we will provide you a one-time commuting allowance of $252,000. You will be responsible for all expenses associated with commuting from your home to our Connecticut office. We will process this payment within 90 days of your start date. This payment will not be included as income for purposes of calculating any other bonus or determining compensation for any benefit plan purposes, and will be subject to applicable tax withholdings. As a condition of payment, you must agree by your signature below that you will repay to Zimmer Biomet the entire gross amount paid to you if you voluntarily leave employment or if your Zimmer Biomet employment is terminated for cause prior to the two-year anniversary of the date Zimmer Biomet makes this payment to you.

Relocation Assistance

We anticipate your relocation to the Connecticut area in approximately three years. Zimmer Biomet will assist you with your relocation to the Connecticut area by paying for reasonable moving expenses in accordance with our Relocation Policy for executives at the level of the role we are offering you. Given the one-time commuting allowance described above, this relocation assistance will be limited to the cost of moving your household goods and costs associated with your home sale and purchase. Please advise us when you want to begin the relocation process.

Executive Officer (Section 16)

We expect that you will be designated by the Board of Directors as an “officer” of Zimmer Biomet for purposes of Rule 16a-1(f) and as an “executive officer” for purposes of Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

As an executive officer, you will be subject to stock ownership guidelines established by the Board of Directors in order to align the interests of executive officers more closely with those of stockholders. The guidelines will require you to own shares with a value equal to at least three times your base salary. You will have up to five years to achieve the required level of stock ownership. Further, every executive officer must obtain clearance prior to selling any shares of Company common stock, in part to ensure that all officers remain in compliance with the stock ownership guidelines. This stock ownership guidelines are subject to annual review by the Compensation Committee.

Section 409A

To the extent that any payments or benefits described in this letter are deemed to be subject to Section 409A of the Internal Revenue Code, this letter will be interpreted in accordance with Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder in order to (a) preserve the intended tax treatment of the benefits provided with respect to such payments and (b) comply with the requirements of Section 409A. A termination of employment shall not be deemed to have occurred for purposes of any provision of this letter providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A. Nothing in this letter shall be construed as a guarantee by the Company of any particular tax effect. The Company shall not be liable to you for any tax, penalty, or interest imposed on any amount paid or payable hereunder by reason of Section 409A, or for reporting in good faith any payment made under this letter as an amount includible in gross income under Section 409A.

 

LOGO    Page 5 – June 13, 2019


LOGO

 

Contractual Obligations

Zimmer Biomet takes its employees’ obligations to former employers very seriously. We respect and honor all enforceable obligations. We understand that you are a party to an Employee Confidential Information and Noncompetition Agreement (the “Other Employer Agreement”) with Bristol-Myers Squibb (the “Other Employer”). Zimmer Biomet requires that you comply fully with any enforceable non-competition, customer and/or employee non-solicitation, and non-disclosure obligations you have to any third party, including the Other Employer.

Zimmer Biomet requires you to refrain from using or sharing any other organization’s confidential information with anyone at Zimmer Biomet. In performing your job responsibilities for Zimmer Biomet, you must not use or disclose to anyone at Zimmer Biomet such information. Before your first day of employment with Zimmer Biomet you must return all Other Employer property and confidential and trade secret information, whether in paper or electronic form, to the Other Employer or delete or dispose of it in accordance with the Other Employer’s direction. Should you later find any Other Employer confidential or trade secret information that you inadvertently failed to return, delete or dispose of before beginning work with Zimmer Biomet, you must immediately alert an appropriate representative of the Other Employer for direction on how to return, delete or dispose of that information and notify a Zimmer Biomet Legal team member that you have done so, without disclosing any of the actual confidential or trade secret information.

To the extent your Other Employer Agreement is enforceable, it imposes certain restrictions on you for a period of time after terminating your relationship with the Other Employer. In accepting the position Zimmer Biomet has offered you, you are representing and warranting to Zimmer Biomet that you can do so without violating any enforceable provisions of the Other Employer Agreement. Please notify us promptly should the Other Employer express any objections to your employment with Zimmer Biomet as inconsistent with terms of the Other Employer Agreement, so that we may assist you in addressing any concerns. If you have questions at any time regarding compliance with the Other Employer Agreement, you should promptly seek guidance from an appropriate member of Zimmer Biomet’s Legal Department.

Benefits

Zimmer Biomet provides a wide range of compelling and competitive benefits, with many of the benefits effective on your first day of active employment. Once you begin employment, you will receive an enrollment package from Zimmer Biomet Benefits Services (“ZBS”), Zimmer Biomet’s group benefits services administrator, regarding your medical, dental, and other group benefits. In addition, you will receive an enrollment package for our 401(k) plan, the Zimmer Biomet Holdings, Inc. Savings and Investment Program, from Fidelity, our 401(k) services administrator. If you do not receive these mailings within two weeks of your hire date, please contact ZBS at 1-877-588-0933 or Fidelity at 1-800-835-5095. You must enroll in the various medical plans within 31 calendar days of your start date.

You are eligible for four weeks of vacation per calendar year, with the opportunity to earn additional weeks of vacation based on years of service. See our holiday and vacation policy for additional details.

 

LOGO    Page 6 – June 13, 2019


LOGO

 

Conditions of Offer

As a condition of and in consideration for employment with Zimmer Biomet, you must accept and sign the enclosed non-disclosure, intellectual property and restrictive covenant agreement. Our offer of employment is also contingent upon receipt of satisfactory background check and drug screen results, subject to Zimmer Biomet’s policies. After you have accepted this offer, you will be contacted to schedule the time and location of the drug screen. Zimmer Biomet considers the result to be an employment record and, while Zimmer Biomet maintains the confidentiality of this record, it is not considered protected health information under HIPAA privacy rules.

Conflicts of Interest Policy and Reporting Requirements

Prior to commencing employment you must, in accordance with the Company’s Conflicts of Interest Policy and based on the nature and level of the role you will assume, disclose any Close Personal Relationship you have with any Company employee. You must also disclose to Human Resources any such Close Personal Relationship with a leased staff person assigned to work for Zimmer Biomet or with a Zimmer Biomet contractor.

You must also disclose any Close Personal Relationship or other potential conflict (e.g., a non-Zimmer Biomet business relationship) that you have with any Healthcare Professionals or other Public Officials, or any other potential conflicts (e.g., ownership or investment in a Zimmer Biomet supplier or business partner) that might interfere or appear to interfere with your employment with Zimmer Biomet. Human Resources and/or Compliance will determine whether the disclosed relationship poses an actual or potential conflict of interest, and if so, what will be done to address the conflict.

For purposes of this policy, a “Close Personal Relationship” is defined as a parent, sibling, child, grandparent, or grandchild, whether by birth or adoption; a similar step- and half- relative or in-law; a spouse or domestic partner; or an individual with whom the Team Member is involved in a romantic and/or sexual relationship. Additionally, for purposes of this policy, a “Healthcare Professional” is defined as an individual, entity, or employee of such entity, within the continuum of care of a patient, which may purchase, lease, recommend, use, prescribe, or arrange for the purchase or lease of Zimmer Biomet products and services. For purposes of this policy, a Public Official is defined as any officer, agent, or employee or any person acting for or on behalf of: (1) a government, including any legislative, administrative, or judiciary branch of such government; (2) any department, agency, or instrumentality of a government, including wholly or majority state-owned or controlled enterprises; (3) any public international organization, such as the United Nations or World Health Organization; (4) a political party (including the political party itself); or (5) any candidate for political office.

General Information and Additional Enclosures

Zimmer Biomet is a federal contractor subject to Section 503 of the Rehabilitation Act of 1973 and as such, we are required to extend to applicants post-offer invitations to identify themselves as individuals with disabilities or as disabled veterans, Vietnam-era veterans, or recently-separated veterans. Providing this information is voluntary, and any information provided in response to this invitation will be kept confidential in accordance with the law. Failure or refusal to provide this information will not have an adverse effect on your employment. This information will be used only for legal purposes.

 

LOGO    Page 7 – June 13, 2019


LOGO

 

The Immigration Reform and Control Act of 1986 requires that employers verify the legal status of all individuals beginning employment. This verification process is accomplished by reviewing certain types of documents to establish identity and legal authorization to work in the United States. Enclosed is Form I-9, which lists the documents you may provide for verification of employment eligibility and for proof of birth date. Please review this list and be prepared to provide the applicable original document(s) after you accept this employment offer and no later than the third day of your employment.

Please note that all benefits are subject to the terms and conditions of the plan document or insurance policy, as amended from time to time. If there is any discrepancy between this letter and the plan documents, the plan documents will govern. While Zimmer Biomet intends to continue benefits referenced in this offer, we reserve the right to change or discontinue them at any time for any reason.

This letter does not create or constitute a contract of employment between you and Zimmer Biomet. Employment with Zimmer Biomet is “at will,” which means that either you or Zimmer Biomet may terminate the employment relationship at any time for any reason, with or without cause or notice.

We are very excited to have you join us and are looking forward to receiving your signed offer letter. We believe you will make a valuable contribution and find your career with Zimmer Biomet challenging and rewarding.

CONFIRMATION OF ACCEPTANCE

Please indicate your acceptance of this offer by signing below and returning the signed letter to me by Tuesday, June 18, 2019. At the same time, please also return your signed non-disclosure, intellectual property and restrictive covenant agreement.

This written offer voids and supersedes any previous written or oral employment offers.

Sincerely,

/s/ Pamela S. Puryear

Pamela S. Puryear

Senior Vice President, Chief Human Resources Officer

Accepted:

 

/s/ Suketu Upadhyay

     

        June 17, 2019

Suketu Upadhyay       Date

Enclosure: Non-disclosure, intellectual property and restrictive covenant agreement

 

LOGO    Page 8 – June 13, 2019

Exhibit 99.1

 

LOGO

345 E. Main St.

Warsaw, IN 46580

www.zimmerbiomet.com

Contacts:

 

Media    Investors
Wendy Wilson    Cole Lannum
574-373-3798    574-371-9480
wendy.wilson@zimmerbiomet.com    cole.lannum@zimmerbiomet.com
  

Barbara Goslee

574-371-9449

barb.goslee@zimmerbiomet.com

Zimmer Biomet Announces Chief Financial Officer Transition Plan

Suketu Upadhyay Appointed Chief Financial Officer, Effective July 1, 2019, Succeeding Daniel Florin

WARSAW, Ind., June  19, 2019 —Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Daniel P. Florin will be retiring as Executive Vice President and Chief Financial Officer of the Company, effective July 1, 2019. Suketu (Suky) Upadhyay has been appointed to succeed Mr. Florin. To ensure a smooth and successful transition, and to assist in executing several ongoing cross-functional financial and operational initiatives, Mr. Florin will continue with the Company in an advisory capacity for a period following the succession.

Bryan C. Hanson, President and CEO of Zimmer Biomet said, “Dan Florin has been my right hand since I joined Zimmer Biomet. He is an outstanding leader and has made significant contributions to Zimmer Biomet over his 12 years with the Company. As we have worked together tirelessly to reshape the organization over the last 18 months, I have been impressed by, and grateful for, his leadership, as well as his advice and counsel to me personally. Dan has been a true partner and I can’t thank him enough for the work he has done to help position our company for greater levels of growth and value creation in the future.

 

1


I look forward to continuing to work with him on several critical projects during this transition period.”

“It has been a privilege to be a part of the Zimmer Biomet family, and I am very proud of our achievements,” said Mr. Florin. “The Company is on a solid path given the team’s progress in accelerating the business and re-establishing the Company as a trusted partner within the industry. With the progress we have made over the past 18 months, I have decided that this is the right time for me to retire so I can focus on priorities outside of my professional career, and spend more time with my family. I look forward to my next chapter, just as I look forward to the Company’s continued success.”    

Mr. Upadhyay is a seasoned healthcare executive with more than two decades of senior financial leadership experience in corporate finance and accounting roles. Mr. Upadhyay currently serves as Senior Vice President, Global Financial Operations of Bristol-Myers Squibb. In this role, he drove strategic and operational initiatives across Bristol-Myers Squibb’s supply chain, commercial operations and R&D resulting in improved resource allocation for growth, reduced costs and margin improvement. Prior to that, he served as Executive Vice President, Chief Financial Officer at Endo International, responsible for all finance functions, investor relations, procurement and information technology. In addition, Mr. Upadhyay previously held leadership positions at Becton Dickinson & Company as Controller and Chief Accounting Officer and as Interim Chief Financial Officer. He has also held leadership roles with Johnson & Johnson and AstraZeneca. He started his career with KPMG and has held the designations of Certified Public Accountant and Certified Management Accountant.

Mr. Hanson continued, “We are pleased to welcome a leader of Suky’s caliber to Zimmer Biomet. He brings extensive leadership experience, financial acumen, knowledge of the healthcare space and deep expertise with multinational organizations that will be beneficial for Zimmer Biomet. We are confident that Suky is the right person to be our next Chief Financial Officer and look forward to his contributions as we continue to transition to offense and position ourselves to deliver significant value to shareholders.”

“I am excited to join Zimmer Biomet at this important time in the Company’s transformation,” said Mr. Upadhyay. “I was attracted to Zimmer Biomet because of the Company’s significant opportunity to leverage its differentiated ecosystem of customer-centric solutions to help accelerate growth and provide true value to customers and patients. I look forward to working with Bryan and the rest of the leadership team to strive to further enhance the Company’s financial and operational performance, and position Zimmer Biomet for continued success.”

 

2


About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet .

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of federal securities laws, including, among others, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2018. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this release.

ZBH-Corp

 

3